Vitamin D3 for Life

Live Enlightened

Article

Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Study Summary

Previous related pageVitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Full StudyNext related pageVitamin D Supplementation and Clinical Iron Markers Across Populations: Full Study
Study at a glance

How might vitamin D affect the release of iron from cells?

This page summarises laboratory and human evidence about vitamin D and the release of iron from cells. Hepcidin reduces iron release by acting on ferroportin, the protein that lets iron leave cells. Lower hepcidin may make iron more available in the blood even when the total amount of iron stored in the body has not changed.

What did laboratory experiments show about vitamin D and iron release?

In liver and immune cells grown in the laboratory, vitamin D reduced activity of the gene that makes hepcidin. Further experiments supported a direct effect through the vitamin D receptor, which receives vitamin D signals inside cells. Ferroportin protein increased as activity of the hepcidin gene decreased. This supports a way for vitamin D to influence iron release.

How did vitamin D affect hepcidin in people?

In a small experiment, a single 100,000 IU dose of vitamin D2 was followed by about 34% lower blood hepcidin within 24 hours. A later trial randomly assigned 28 healthy adults to a single 250,000 IU dose of vitamin D3 or an inactive treatment. After one week, hepcidin had fallen about 73% from its starting value in the vitamin D group. The comparison group did not show a significant reduction. These were research doses, not instructions for personal use.

Does lower hepcidin mean anaemia has been corrected?

Ferritin, a measure related to iron stores, and measured inflammation signals did not change significantly in the later trial. Lower hepcidin does not guarantee correction of anaemia. Producing haemoglobin, the oxygen-carrying substance in red blood cells, also depends on iron stores, kidney and bone-marrow function, inflammation and other nutrients. The evidence does not support replacing diagnosis or treatment of iron deficiency or anaemia with vitamin D.

Read the full article below ↓

Hepcidin determines how readily iron can leave intestinal cells and macrophages and become available in the circulation. Vitamin D signalling can interact directly with this regulatory system. Experimental evidence shows suppression of the hepcidin gene HAMP through vitamin-D-receptor-related transcriptional mechanisms, while human supplementation studies show rapid falls in circulating hepcidin after high-dose vitamin D exposure. This creates a specific mechanistic connection with Vitamin D and Iron Metabolism. For the detailed evidence review, see Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Full Study.

Why hepcidin matters

Hepcidin binds to ferroportin, the major cellular iron exporter. Increased hepcidin reduces iron release from intestinal cells and iron-recycling macrophages. Lower hepcidin permits greater potential iron export. This means circulating iron availability can change even when total iron stores have not changed.

Inflammation can raise hepcidin and contribute to functional iron restriction, which connects this pathway with Vitamin D and Inflammatory Signalling.

Vitamin D can suppress the hepcidin gene

Bacchetta and colleagues found that 25(OH)D and 1,25(OH)₂D reduced HAMP messenger RNA in cultured hepatocytes and monocytes. Promoter and chromatin experiments supported direct transcriptional regulation through vitamin D receptor signalling. Reduced HAMP expression was accompanied by increased ferroportin protein.

In a small human experiment, a single 100,000 IU dose of vitamin D₂ increased circulating 25(OH)D and was followed by an approximately 34% fall in hepcidin within 24 hours.

Randomized evidence reproduced the hepcidin effect

A subsequent randomized placebo-controlled trial in 28 healthy adults used a single 250,000 IU dose of vitamin D₃. Hepcidin fell by approximately 73% from baseline after one week in the vitamin-D group, while the placebo group did not show a significant reduction.

Ferritin and measured inflammatory cytokines did not change significantly. The result therefore supports an effect on hepcidin that cannot be explained simply by rapid depletion of iron stores or by a measurable general reduction in those cytokines.

A hepcidin response is not the same as correcting anaemia

Lowering hepcidin may increase the physiological opportunity for iron mobilisation, but haemoglobin production depends on iron stores, erythropoietin, bone-marrow function, renal physiology, inflammation and other nutrients. A molecular effect therefore does not guarantee a whole-body clinical result.

This is one example of the broader distinction described in Vitamin D Status vs Vitamin D Effect. It also explains why later trials in chronic disease can produce different results despite a credible mechanism.

The strongest conclusion is that vitamin D can participate in regulation of the hepcidin-ferroportin axis. It is not evidence that vitamin D supplementation should replace diagnosis or treatment of iron deficiency or anaemia.

Scientific sources

Adriana Bacchetta and colleagues. Suppression of iron-regulatory hepcidin by vitamin D. PMID: 24204002.

Jessica A Alvarez and colleagues. High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. PMID: 27402475.

Related reading

Original sources